Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Operating activities
Net income		$ 44,278	$ 26,478
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and finance lease amortization		20,652	17,152
Amortization of intangible assets		25,489	24,750
Amortization of deferred financing costs and original issue discount		636	973
Change in fair value of investment		9,947	6,019
Deferred income taxes		(4,182)	(5,405)
Share-based compensation expense	[1]	11,608	12,440
Loss (gain) on disposal of assets		303	(52)
Other noncash charges		626	1,410
Excess tax (benefits) expense from equity awards		(164)	1,009
Net changes in operating assets and liabilities:
Accounts receivable		48,350	13,664
Inventories		(57,203)	(18,109)
Other assets		2,145	(920)
Accounts payable		(33,007)	44,682
Accrued wages and employee benefits		(31,554)	(8,512)
Other accrued liabilities		20,228	(3,681)
Net cash provided by operating activities		58,152	111,898
Investing activities
Proceeds from sale of property and equipment		54	51
Contribution to tax equity investment		0	(1,629)
Purchase of long-term investment		(2,656)	(239)
Proceeds from sale of long-term investment		0	2,000
Expenditures for property and equipment		(30,937)	(26,820)
Net cash used in investing activities		(33,539)	(26,637)
Financing activities
Proceeds from short-term borrowings		19,236	8,970
Proceeds from long-term borrowings		943	471
Repayments of short-term borrowings		(19,985)	(18,489)
Repayments of long-term borrowings and finance lease obligations		(14,450)	(7,030)
Stock repurchases		(97,454)	0
Payment of deferred acquisition consideration		0	(6,000)
Purchase of additional ownership interest		0	(9,117)
Taxes paid related to equity awards		(8,601)	(5,455)
Proceeds from the exercise of stock options		592	319
Net cash used in financing activities		(119,719)	(36,331)
Effect of foreign exchange rate changes on cash and cash equivalents		1,293	(569)
Net (decrease) increase in cash and cash equivalents		(93,813)	48,361
Cash and cash equivalents at beginning of period		281,277	200,994
Cash and cash equivalents at end of period		$ 187,464	$ 249,355

[1] Represents share-based compensation expense to account for stock options, restricted stock, and other stock awards over their respective vesting periods.